Citron tweets Valeant has better chance of going to zero than Herbalife ever will
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- Harry and Meghan surprised by King Charles' letter on their status
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Citron Research: Don't Expect Anything Earth-Shattering on Valeant (VRX) Come Monday
November 1, 2015 7:32 PM ESTCitron Research's Andrew Left is dialing back on what investors should expect when he updates his report on battered Valeant Pharma (NYSE: VRX) on Monday.
During Bill Ackman's 4-hour defense of Valeant on Friday, short seller Left tweeted: "$VRX has a... More
Valeant Pharma (VRX) Trades Near Lows Heading Into Weekend
October 30, 2015 3:23 PM EDTValeant Pharma (NYSE: VRX) fell to session lows in the final hour of trading. Earlier Citron said it plans to update its short report on Monday, claiming the company is "dirtier than has been reported." Concerns about the possible release of new information set... More
Citron's Left Will be on CNBC Monday to Talk About Valeant (VRX)
October 30, 2015 12:27 PM EDTCitron's Andrew Left will be back on CNBC's Halftime Report on Monday, November 2nd, to talk about his upcoming report on Valeant Pharma (NYSE: VRX).
... More